全新综述文章介绍干细胞疗法在神经疾病治疗方面的进展

2016-09-22 佚名 生物谷

据一篇发表在国际学术期刊Human Gene Therapy上的综述文章介绍,将治疗性干细胞直接移植到中枢神经系统是治疗溶酶体贮积症(lysosomal storage diseases)造成的神经疾病的一个非常具有前景的新方法,不过将基于LSD动物模型开发的干细胞治疗方法转化为用于人类疾病治疗的有效方法仍然面临着许多重大挑战。这篇文章题为“Stem Cell Therapy for the Ce


据一篇发表在国际学术期刊Human Gene Therapy上的综述文章介绍,将治疗性干细胞直接移植到中枢神经系统是治疗溶酶体贮积症(lysosomal storage diseases)造成的神经疾病的一个非常具有前景的新方法,不过将基于LSD动物模型开发的干细胞治疗方法转化为用于人类疾病治疗的有效方法仍然面临着许多重大挑战。

这篇文章题为“Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases”,是Human Gene Therapy和Stem Cells and Development上干细胞基因治疗特刊的一部分。

溶酶体贮积症(LSD)是一组遗传性代谢疾病,是由于基因突变致溶酶体中有关酸性水解酶缺陷,导致机体中相应的生物大分子不能正常降解而在溶酶体中贮积,引起细胞组织器官功能的障碍。目前已知溶酶体贮积症至少包含50种不同的单基因遗传病。

文章共同作者Faez Siddiqi和John Wolfe在这篇综述文章中对可以用于治疗神经疾病的不同干细胞类型进行了讨论。他们回顾总结了一些最新的研究进展,描述了科学家们在神经干细胞工程改造以及如何将干细胞导入中枢神经系统,使得干细胞对LSD病人的治疗能力达到最优化方面做出的努力。

“LSD在之前被认为是影响脑的一种不可治愈疾病,而干细胞治疗研究的不断发展为病人和他们的家庭提供了希望,”主编Terence R. Flotte这样说道。“许多动物研究已经证明了直接注射干细胞能够逆转这些疾病的影响,而利用酶替换方法无法达到治愈这类疾病的目的。Siddiqi和Wolfe博士的这篇综述对干细胞疗法的希望和局限做出了非常实际和深入的评价。”

原始出处 

Faez Siddiqi1 and John H. Wolfe1,2,*.Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.Human Gene Therapy。2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 知难而进

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 知难而进

    继续关注!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1982755, encodeId=04f81982e5565, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 27 22:31:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314455, encodeId=b897131445596, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613953, encodeId=255d161395350, content=<a href='/topic/show?id=f587e438580' target=_blank style='color:#2F92EE;'>#神经疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74385, encryptionId=f587e438580, topicName=神经疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ea719457876, createdName=新生儿张玉军, createdTime=Sat Sep 24 11:31:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133710, encodeId=15d4133e1067, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133711, encodeId=7dc4133e1173, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 23 16:25:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133331, encodeId=415713333192, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 23 09:26:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 刘煜

    学习了谢谢。

    0

相关资讯

Lancet:Ixmyelocel-T细胞疗法或将是HFrEF患者的福音

美国心脏病学会年会上称,ixCELL-DCM试验2b阶段,心内膜注射ixmyelocel-T细胞治疗因缺血性扩张型心肌病导致射血分数减少的HF患者(HFrEF),可减少心脏事件的发生(与安慰剂相比)。该随机、双盲、安慰剂对照试验纳入了126名HFrEF患者,其左心室射血分数减少至35%,有植入型心律转复除颤器,不能行血管再生治疗。研究人员将其随机分为ixmyelocel-T (Vericel)组或

JAMA:细胞疗法不能改善外周动脉疾病患者的行走能力

芝加哥– 亚特兰大埃默里大学医学院的Joseph Poole, M.D., Ph.D.及其同事对粒细胞 - 巨噬细胞集落刺激因子(GM-CSF)——这是一种作用为白血病生长因子的物质——疗法是否能改善症状性外周动脉疾病(这是一种血管疾病,在这种疾病中通常有一根通往大腿或手臂的动脉发生部分或全部的堵塞)患者的行走能力进行了研究。 根据文章的背景资料:“在美国,受外周动脉疾病(PAD)影响的人超过8

癫痫: 基因疗法VS细胞疗法

癫痫是神经系统常见疾病之一,患病率仅次于脑卒中。癫痫的发病率与年龄有关。一般认为1岁以内患病率最高,其次为1~10岁以后逐渐降低。我国男女之比为1.15∶1~1.7∶1。 而如今随着生物科学技术的不断进步,癫痫病的治疗手段得到了突飞猛进的发展。目前在国际上治疗癫痫主要分为2个流派:基因疗法&细胞疗法。 基因疗法 2014年1月23日的EurekAlert报告:性激素雌二醇或能阻止

ASCO 2015:CAR-T细胞疗法正在攻克实体瘤 胰腺癌是初露曙光

近年来,嵌合抗原受体(CAR)-T细胞治疗已经多次在血液肿瘤方面表现出了令人惊叹的治疗效果。而在实体瘤方面,却没有成功的案例。令人惊喜的是,在2015年美国临床肿瘤学会年会上,公布了CAR T细胞首次在实体肿瘤——胰腺癌治疗上的突破。此前报道:Car-T治疗实体肉瘤:细胞存活超过六周且无明显毒性反应至于CAR-T细胞治疗用于实体瘤的效果能否达到像在急性淋巴细胞白血病或非霍奇金淋巴瘤中达到的70%之

Nature:这个蛋白可支招糖尿病细胞疗法

众所周知,胰岛中的β细胞会在血糖升高时释放胰岛素,以控制血糖水平。如果这些细胞受损或失能,则会严重削弱机体的血糖调控能力,从而导致糖尿病。 不过,胰岛β细胞并非“铁板一块”,而是具有相当的异质性。这些细胞在大小、对血糖的反应性、胰岛素分泌和分化潜力等方面均具有明显的差异性。 “人们早就知道,胰岛β细胞是可以被分成各种亚群的,”德国亥姆霍兹慕尼黑中心(Helmholtz Zentrum Mün

STM:细胞疗法根除癌症传新捷报

来自纪念斯隆-凯特琳癌症中心的研究人员,报告了与最令人兴奋的一种癌症治疗方法有关的一则鼓舞人心的消息。这项迄今为止针对晚期白血病患者的最大型临床研究发现,在用患者自身经遗传修饰的免疫细胞治疗之后88%的患者获得了完全缓解。这些研究结果发表在《科学转化医学》(Science Translational Medicine)杂志上。【原文下载】 论文的资深作者之一、纪念